Outlive came out in 2023. It is still the best mainstream longevity framework book in print, and most of it has aged well. Three years on, several specific pieces of evidence have moved — in two cases substantially. This is what an honest reader should add to their understanding.
A note before we start: this page is not a takedown. Peter Attia is the most clinically careful longevity practitioner writing for a general audience, and his Medicine 3.0 framework is the right north star for adults over 40. Three years on, several specific pillars of the book benefit from an evidence refresh — not because Attia was wrong, but because the data moved.
I’m writing this for the reader who’s already read Outlive, taken it seriously, and wants to know what to add to their mental model in 2026. If you haven’t read Outlive, do that first — the book’s framing of mortality, the Four Horsemen, and the case for proactive measurement is more important than any specific intervention update.
Most of Outlive hasn’t needed updating at all. These pieces are exactly as right in 2026 as they were in 2023 — in several cases more so.
If you take only the bones of Outlive — the framework, the four horsemen, the emphasis on movement, strength, sleep, and emotional health — you have a longevity practice that nothing in the last three years has invalidated.
This is the biggest single shift since Outlive went to press. Attia’s book discusses semaglutide briefly, but the major cardiovascular outcomes data didn’t exist yet.
Lincoff et al., NEJM, 2023. In 17,604 adults with overweight or obesity plus established cardiovascular disease but without diabetes, semaglutide 2.4mg weekly reduced the primary cardiovascular endpoint (MACE: death, MI, stroke) by 20% compared with placebo over a median 40 months. This trial published almost simultaneously with Outlive’s release and was the first major outcome trial of a GLP-1 agonist in non-diabetic patients.
The implication: GLP-1 agonists are no longer just “diabetes drugs that help with weight loss.” They’re increasingly understood as one of the most powerful pharmacological tools for cardiovascular risk reduction in adults with obesity-driven mortality risk — the kind of intervention that fits perfectly inside Attia’s Medicine 3.0 framework but wasn’t available to discuss in detail in the book.
Subsequent signals (still developing, less firm than SELECT) suggest possible benefits in reducing certain cancers (ASCO GI 2026 shows 16% fewer colon cancers vs DPP-4i), dementia incidence, and addiction-related behaviors. The 2025 SELECT adiposity subgroup analysis showed the cardiovascular benefit holds regardless of baseline BMI and is largely independent of the amount of weight lost — meaning the mechanism appears to be a direct vascular/inflammatory effect, not a pure weight-loss artifact.
Attia’s own current public position (AMA #64, 2024-2025) is supportive but with an explicit caveat that fits his strength-and-mass framework: resistance training and high protein intake become mandatory, not optional, the moment you start a GLP-1. The 2025 SURMOUNT-1 DXA substudy quantified why: tirzepatide reduced lean body mass by 10.9% over 72 weeks, with roughly 25% of weight lost coming from muscle. A 2025 prospective study found that combining GLP-1 initiation with resistance training and protein education cut lean loss from ~25% to 3%. That is the protocol Attia’s framework demands.
What this means for you: If you have meaningful overweight/obesity plus cardiovascular risk factors, the GLP-1 conversation deserves a place at the table with your physician that it didn’t fully have when Outlive was being written. If you do start, the protein and resistance-training side is non-negotiable. Our separate page on GLP-1 agonists for aging covers the full 2026 evidence picture — including the FDA’s January 2026 clearance of the suicidality signal, the new NAION and gastroparesis label additions, and the bone-density loss data.
Attia is on record as a personal rapamycin user and has been transparent about that since 2019. The book frames rapamycin as the most-studied compound in animal longevity research with promising but unproven human application. That framing is still correct, but the data have meaningfully sharpened.
Mannick & Lamming et al., Aging (Albany NY), April 2025. PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity), the largest randomized human trial of low-dose intermittent rapamycin to date: n=114, 48 weeks, 5 mg or 10 mg weekly compounded rapamycin vs placebo. The primary endpoint — change in visceral adiposity — did not meet statistical significance (p=0.942). Secondary signals emerged in subsets (modest lean mass improvement and pain reduction in women on the 10 mg arm), but the trial did not demonstrate the headline benefit it was designed to test. A critical caveat: the compounded formulation used has roughly one-third the bioavailability of commercial sirolimus, so the dose tested was effectively much lower than the dose Attia and others actually take.
Attia’s own public commentary in 2025 reflects the shift — he describes rapamycin as “promising” rather than endorsed, and notes that only about 5% of his clinical patients take it. On the December 2024 episode with David Sabatini and Matt Kaeberlein (#272 of his podcast), the conversation explicitly acknowledged we are “a long way from being able to say rapamycin is geroprotective in humans.” Attia’s commentary on a separate rapa+exercise trial called those results “disappointing.”
The honest reading: PEARL is the first large RCT of low-dose rapamycin in humans, and the primary endpoint failed. That’s real evidence, not a non-event. The bioavailability caveat is important, but a failed primary endpoint in your highest-powered human trial is the kind of result that should make a careful reader less, not more, confident in the intervention. Rapamycin remains the most promising longevity-relevant drug in animal models. It is not yet recommendable for adults outside a research setting, and the case is incrementally weaker, not stronger, than it was in 2023.
Outlive presents CGM use as a window into metabolic health that’s worth considering for adults concerned about metabolic dysfunction. Three years of subsequent research has been less kind to this idea.
Multiple reviews and small trials since 2023 have failed to show that CGM-guided dietary or behavioral changes improve clinical outcomes in metabolically healthy adults. Most non-diabetics have small post-meal glucose excursions that don’t correlate with disease risk in any clinically actionable way. The behavioral biofeedback case is reasonable; the longevity intervention case is weaker than it appeared in 2023.
This isn’t a refutation of Attia’s broader point about metabolic measurement — ApoB, fasting insulin, HbA1c, OGTT remain useful. It’s a refinement of one specific tool. Use CGM if it helps you choose foods you wouldn’t otherwise; don’t expect the data itself to change your trajectory.
Two areas where evidence-based clinicians I respect read the same studies differently than Attia does. These aren’t corrections — they’re honest disagreements among careful people.
Attia recommends roughly 1g of protein per pound of body weight (about 2.2 g/kg) as a target for adults focused on muscle preservation. Outlive argued for it; the August 2025 article on his site is even more emphatic, framing the case against high protein intake as “coming out bankrupt.” When the New York Times ran a skeptical piece in late 2025 on the protein craze, Attia declined to engage. Eric Topol’s September 2025 Substack “Our Preoccupation With Protein Intake” pushed back from the cardiology side. This is now a public, unresolved disagreement among careful people.
The 2025 evidence has actually moved toward Attia’s higher number for sarcopenic older adults specifically. Yin et al. (Frontiers in Nutrition, 2025), using indicator amino acid oxidation, calculated a recommended nutrient intake of 1.54 g/kg for sarcopenic older adults — meaningfully above the PROT-AGE 1.0–1.2 g/kg upper bound. A 2024 Korean meta-analysis found sarcopenia risk significantly higher at <0.8 g/kg compared with ≥1.2 g/kg.
The honest synthesis: everyone now agrees protein needs go up with age above the RDA. The remaining live disagreement is whether very high intakes (1.6 g/kg or higher, up to Attia’s ~2.2 g/kg) add meaningful benefit beyond modest elevation for healthy adults — or whether Topol-style cardiology concerns outweigh marginal muscle-preservation gains. For most readers, the practical difference between “PROT-AGE” and “Attia” is 90g vs 150g per day for a 150-lb adult. Both are dramatic improvements over the 50–60g most older adults actually consume. The biggest factual update since 2023 is that Attia hasn’t backed off, and the 2025 sarcopenia-specific evidence has cautiously moved his way.
Attia’s framing of ApoB-driven cardiovascular prevention as “the earlier the better” is well-evidenced in the genetic LDL-lowering literature. The 2025 multi-society lipid management guideline update (AHA / ACC, March 2025) moved meaningfully toward his position: lowered statin-eligibility age toward 30 in patients with elevated risk markers and recommended universal one-time Lp(a) testing. Both changes vindicate the Outlive thesis.
Some cardiologists still read the absolute risk reduction data more conservatively for younger lower-risk patients, particularly women under 60 with no other risk factors — but the center of clinical opinion has shifted toward earlier intervention, not away from it. Attia’s ApoB targets remain on the aggressive end (under 60 mg/dL, 20-40 in high-risk patients), but the “intervene earlier rather than later” principle is now mainstream.
This is the cleanest example of a major Outlive position being strengthened, not refined, by post-publication evidence and guideline updates.
The short version. Outlive remains the single best mainstream book on living longer and better. Read it. Use the framework. Adopt the strength, aerobic, sleep, and emotional pillars. Get the ApoB, fasting insulin, and other markers checked. Then update four things the book either predated, undersold, or got partially wrong: the GLP-1 conversation if it applies to you (now with the muscle-and-bone-protection protocol baked in), the rapamycin reality (PEARL’s primary endpoint failed in April 2025, and Attia himself now hedges to “promising”), skepticism about CGM as a longevity tool in healthy adults, and the recent guideline shift that vindicated the early-statin/Lp(a) position.
If you want a single sentence: the framework book is right; one chapter (GLP-1 agonists, with the protein/RT mandate) needs to be added; one chapter (CGM for non-diabetics) needs to be softened; the rapamycin chapter needs to be hedged; and the early-statin chapter just got mainstream endorsement.
The Over-50 Reverse-Aging Guide takes the best parts of Outlive and adds the practical “here’s how an actual adult over 50 should think about this” layer Attia’s book left to the reader.
See the Full GuideYes. The framework — Medicine 3.0, Four Horsemen, exercise as drug, sleep and emotional health as pillars — has aged well. Update your mental model with the three areas covered above (GLP-1 agonists, rapamycin human data, CGM evidence) and you’ll be current.
Three big shifts: GLP-1 agonists (semaglutide, tirzepatide) have published major cardiovascular outcome data and are now central to obesity-driven risk reduction in ways the book predated; rapamycin human trials have published mixed early results; CGM evidence for non-diabetics has weakened, with several reviews questioning whether CGM-guided changes improve long-term outcomes in healthy adults.
His direction is right, and he is publicly doubling down, not walking back. His August 2025 article frames the case against high protein intake as “coming out bankrupt.” The 2025 Yin et al. study using indicator amino acid oxidation calculated a recommended intake of 1.54 g/kg for sarcopenic older adults — meaningfully above the PROT-AGE 1.0–1.2 g/kg upper bound. Eric Topol pushed back from the cardiology side in September 2025; Attia did not engage. The remaining live disagreement is the very-high end (1.6–2.2 g/kg).
His current public position (AMA #64, 2024-2025) is supportive, with a hard mandate that fits his framework: resistance training and high protein intake become mandatory the moment you start. The 2025 SURMOUNT-1 DXA substudy showed tirzepatide reduced lean body mass 10.9% over 72 weeks with about 25% of weight lost coming from muscle. A 2025 prospective protocol cut that lean loss from ~25% to 3%. That is the protocol Attia’s framework demands.
The April 2025 PEARL trial (n=114, 48 weeks) failed its primary endpoint (visceral adiposity unchanged, p=0.942). Modest secondary signals appeared in subsets. The compounded formulation tested had about one-third the bioavailability of commercial sirolimus — a real caveat — but a failed primary endpoint in the largest human RCT is meaningful negative evidence. Attia himself now describes rapamycin as “promising” rather than endorsed and notes only about 5% of his patients take it. For most adults over 50, this remains a wait-and-watch situation, not a today-decision.
By 2026 standards: the book undersells GLP-1 agonists (now with the obligatory protein/RT protocol); the rapamycin chapter was too optimistic relative to PEARL; the CGM-for-non-diabetics framing has weakened. On the other side, the early-statin/ApoB/Lp(a) framing was vindicated by the March 2025 AHA/ACC guideline update that lowered statin-eligibility age and recommended universal Lp(a) testing. The framework is right; specific dosages and targets are where calibration continues.
— Scott Covert, 60, skeptic, not a physician. I take Outlive seriously and so should you. This page exists because I read the book carefully and wanted to know what had moved since 2023. Got an Attia claim you want me to dig into? Tell me.